2023 article
Vaccination for the prevention of equine herpesvirus-1 disease in domesticated horses: A systematic review and meta-analysis
Osterrieder, K., Dorman, D. C., Burgess, B. A., Goehring, L. S., Gross, P., Neinast, C., … Lunn, D. P. (2023, November 6). JOURNAL OF VETERINARY INTERNAL MEDICINE.
author keywords: equine; equine herpesvirus myeloencephalopathy (EHM); equine herpesvirus-1 (EHV-1); vaccination
TL;DR:
It is indicated that commercial and experimental vaccines minimally reduce the incidence of clinical disease associated with EHV-1 infection.
(via Semantic Scholar)
open access via onlinelibrary.wiley.com (publisher PDF)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science; OpenAlex)
Source: Web Of Science
Added: November 20, 2023
AbstractBackgroundEquine herpes virus type 1 (EHV‐1) infection in horses is associated with respiratory and neurologic disease, abortion, and neonatal death.HypothesisVaccines decrease the occurrence of clinical disease in EHV‐1‐infected horses.MethodsA systematic review was performed searching multiple databases to identify relevant studies. Selection criteria were original peer‐reviewed research reports that investigated the in vivo use of vaccines for the prevention of disease caused by EHV‐1 in domesticated horses. Main outcomes of interest included pyrexia, abortion, neurologic disease, viremia, and nasal shedding. We evaluated risk of bias, conducted exploratory meta‐analyses of incidence data for the main outcomes, and performed a GRADE evaluation of the quality of evidence for each vaccine subtype.ResultsA total of 1018 unique studies were identified, of which 35 met the inclusion criteria. Experimental studies accounted for 31/35 studies, with the remainder being observational studies. Eight vaccine subclasses were identified including commercial (modified‐live, inactivated, mixed) and experimental (modified‐live, inactivated, deletion mutant, DNA, recombinant). Risk of bias was generally moderate, often because of underreporting of research methods, and sample sizes were small leading to imprecision in the estimate of the effect size. Several studies reported either no benefit or minimal vaccine efficacy for the primary outcomes of interest. Meta‐analyses revealed significant heterogeneity was present, and our confidence in the quality of evidence for most outcomes was low to moderate.Conclusions and Clinical ImportanceOur review indicates that commercial and experimental vaccines minimally reduce the incidence of clinical disease associated with EHV‐1 infection.